

# Review of: "Breast Cancer Subtypes And Prognosis: Answers To Subgroup Classification Questions, Identifying The Worst Subgroup In Our Single-Center Series"

Ryong Nam Kim

**Potential competing interests:** The author(s) declared that no potential competing interests exist.

## Comment 1.

The authors should describe the following contents in the discussion section in their revised manuscript.

In diverse types of cancer including breast cancer, the ERBB2 (encoding HER2 protein) is amplified (as copy number amplification), concomitantly harboring gain-of-function mutation or other non-synonymous mutations in many cases of HER2-enriched (ERBB2-amplified) tumors. If such gain-of-function or other non-synonymous mutations in the ERBB2 are to dramatically change the antigen structural conformation in the HER2 protein, which is specifically targeted by Trastuzuma (Herceptin) monoclonal antibody, the HER2-enriched breast cancer patients (with both ERBB2 amplification and the mutations) are resistant to Trastuzuma treatment, and such patients have the worst prognosis.